Is Vincerx Pharma, Inc. (VINC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 7329.0% / 30% | 1529.9% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 7329.0% / 33% | 1529.9% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 62.3% / 33% | 13.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 7329.0% / 33% | 1529.9% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 62.3% / 33% | 13.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -3136.4% | |
| Return on Assets (ROA) | -197.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$26M |
| Free Cash Flow | -$26M |
| Total Debt | $0 |
| Current Ratio | 1.8 |
| Total Assets | $8M |
Price & Trading
| Last Close | $0.01 |
| 50-Day MA | $0.01 |
| 200-Day MA | $0.03 |
| Avg Volume | 3K |
| Beta | 1.6 |
|
52-Week Range
$0.00
| |
About Vincerx Pharma, Inc. (VINC)
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Vincerx Pharma, Inc. (VINC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Vincerx Pharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Vincerx Pharma, Inc.'s debt ratio?
Vincerx Pharma, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Vincerx Pharma, Inc.'s key financial metrics?
Vincerx Pharma, Inc. has a market capitalization of $68,045. Return on equity stands at -3136.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.